Monopar Therapeutics (NASDAQ:MNPR) Director Kim Tsuchimoto Sells 1,199 Shares of Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 1,199 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $70.10, for a total value of $84,049.90. Following the transaction, the director owned 1,199 shares in the company, valued at approximately $84,049.90. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

NASDAQ MNPR opened at $72.81 on Thursday. The stock’s fifty day moving average is $88.66 and its two-hundred day moving average is $77.40. The firm has a market capitalization of $488.56 million, a P/E ratio of -33.55 and a beta of 1.62. Monopar Therapeutics Inc. has a fifty-two week low of $50.07 and a fifty-two week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sei Investments Co. grew its holdings in shares of Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares during the last quarter. Your Advocates Ltd. LLP purchased a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $183,000. The Manufacturers Life Insurance Company purchased a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $250,000. Bank of New York Mellon Corp lifted its position in Monopar Therapeutics by 21.2% during the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after acquiring an additional 13,761 shares during the period. Finally, ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar is projected to announce quarterly earnings on Thursday. The report could give investors an update on the company’s performance; no results or estimates are detailed in the article. Monopar Therapeutics projected to announce quarterly earnings
• Neutral Sentiment: A separate article raises the question of what investment firms think about MNPR, but the provided information does not specify any firms’ ratings, price targets, or recent actions. What investment firms are thinking about MNPR
• Negative Sentiment: Directors reported selling shares: Kim Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2, while Raymond Anderson sold 3,142 shares on Nov. 2. The sales reduced their reported holdings and could concern investors, although the transactions were made under pre-arranged Rule 10b5-1 plans. SEC filing for director transactions

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MNPR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Barclays reissued an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Finally, HC Wainwright raised their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.